Literature DB >> 7681372

Prevention and management of gout.

V L Star1, M C Hochberg.   

Abstract

Gout is a common disease with a worldwide distribution. The major risk factor for the development of gout is sustained asymptomatic hyperuricaemia. Although pharmacological therapy of asymptomatic hyperuricaemia is not recommended, primary prevention of gout can be achieved through lifestyle changes including weight loss, restricting protein and calorie intake, limiting alcohol consumption, avoiding the use of diuretics in the treatment of hypertension, and avoiding occupational exposure to lead. The arthritis of gout can be readily managed with the use of nonsteroidal anti-inflammatory drugs (NSAIDs); systemic steroids or corticotrophin (adrenocorticotrophic hormone; ACTH) should be used in patients with contraindications to NSAIDs, or who are intolerant of them. Because of potential toxicity, colchicine should not be used to treat acute gout, but should be used in low dosage (0.6 to 1.2 mg/day) for prophylaxis of recurrent attacks of gout. The other cornerstone of prevention of recurrent gouty attacks is control of hyperuricaemia, which can be effectively accomplished with antihyperuricaemic therapy. The choice of agents, either uricosuric drugs or xanthine oxidase inhibitors, is based on the level of urinary uric acid excretion, renal function, age of patient, history of renal calculi and presence of tophi. Treatment and prevention of gout are exceedingly effective and patients can usually be managed by their primary care physician.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7681372     DOI: 10.2165/00003495-199345020-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  28 in total

1.  The action of colchicine in acute gouty arthritis.

Authors:  S E Malawista
Journal:  Arthritis Rheum       Date:  1975 Nov-Dec

Review 2.  Gout and hyperuricemia.

Authors:  F Wolfe
Journal:  Am Fam Physician       Date:  1991-06       Impact factor: 3.292

Review 3.  The clinical management of gout.

Authors:  L P Sterling
Journal:  Am Pharm       Date:  1991-05

Review 4.  Treatment of gout and crystal arthropathies and uses and mechanisms of action of nonsteroidal anti-inflammatory drugs.

Authors:  S B Abramson
Journal:  Curr Opin Rheumatol       Date:  1992-06       Impact factor: 5.006

5.  Gout and coronary heart disease: the Framingham Study.

Authors:  R D Abbott; F N Brand; W B Kannel; W P Castelli
Journal:  J Clin Epidemiol       Date:  1988       Impact factor: 6.437

6.  Efficacy of colchicine prophylaxis in gout. Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects.

Authors:  T F YU; A B GUTMAN
Journal:  Ann Intern Med       Date:  1961-08       Impact factor: 25.391

7.  Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.

Authors:  K R Hande; R M Noone; W J Stone
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

8.  Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study.

Authors:  E W Campion; R J Glynn; L O DeLabry
Journal:  Am J Med       Date:  1987-03       Impact factor: 4.965

9.  Colchicine in acute gout. Reassessment of risks and benefits.

Authors:  W N Roberts; M H Liang; S H Stern
Journal:  JAMA       Date:  1987-04-10       Impact factor: 56.272

10.  Incidence and risk factors for gout in white men.

Authors:  R Roubenoff; M J Klag; L A Mead; K Y Liang; A J Seidler; M C Hochberg
Journal:  JAMA       Date:  1991-12-04       Impact factor: 56.272

View more
  7 in total

1.  Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.

Authors:  Reza Khosravan; Brian A Grabowski; Jing-Tao Wu; Nancy Joseph-Ridge; Laurent Vernillet
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 2.  Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol.

Authors:  Pál Pacher; Alex Nivorozhkin; Csaba Szabó
Journal:  Pharmacol Rev       Date:  2006-03       Impact factor: 25.468

3.  Treatment of acute gouty arthritis with the 5-hydroxytryptamine antagonist ondansetron.

Authors:  H Schwörer; G Ramadori
Journal:  Clin Investig       Date:  1994-10

4.  LC-UV-electrospray-MS-MS mass spectrometry analysis of plant constituents inhibiting xanthine oxidase.

Authors:  E Gariboldi; D Mascetti; G Galli; P Caballion; E Bosisio
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

5.  Microwave Heating of Synthetic Skin Samples for Potential Treatment of Gout Using the Metal-Assisted and Microwave-Accelerated Decrystallization Technique.

Authors:  Salih Toker; Zainab Boone-Kukoyi; Nishone Thompson; Hillary Ajifa; Travis Clement; Birol Ozturk; Kadir Aslan
Journal:  ACS Omega       Date:  2016-11-01

Review 6.  Gout in the elderly. Clinical presentation and treatment.

Authors:  A G Fam
Journal:  Drugs Aging       Date:  1998-09       Impact factor: 4.271

Review 7.  A review of antioxidant and pharmacological properties of phenolic compounds in Acacia confusa.

Authors:  Huan-You Lin; Tzu-Cheng Chang; Shang-Tzen Chang
Journal:  J Tradit Complement Med       Date:  2018-06-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.